News
Public · Published
Canaccord Genuity maintains Merit Medical Systems at Buy, raises price target to $121 from $94
Canaccord Genuity kept its Buy rating on Merit Medical Systems and raised its price target to $121 from $94. The new target is 28.7% higher than its previous target and implies 40.3% upside from the October 30 closing price of $86.24.
Published:
Updated:
What happened
Canaccord Genuity kept its Buy rating on Merit Medical Systems and raised its price target to $121 from $94. The new target is 28.7% higher than its previous target and implies 40.3% upside from the October 30 closing price of $86.24.
Confirmed
Global impact / market context
A higher target reflects Canaccord’s more optimistic view of the company’s potential share value, but it is an analyst estimate, not a company forecast or guaranteed return. If investors act on it, buying could support the share price; the article gives no evidence of such a reaction.
Analyst inference
The five other recent analyst notes listed set targets from $90 to $110, while Canaccord’s new $121 target is above that range. This highlights a more optimistic estimate, but differences among analyst views do not establish Merit Medical’s future results or share price.
Confirmed
What to watch
- Compare future analyst targets with company results and outlook; the article provides estimates but no new operating figures that would confirm the higher valuation. Analyst inference
- Check whether other analysts raise their targets or ratings, which could show whether Canaccord’s more optimistic view is becoming more widely shared. Analyst inference
- Watch Merit Medical’s subsequent share price against the stated $86.24 October 30 close and Canaccord’s $121 target; the article reports no later price movement. Analyst inference
Evidence
- Original source link unavailable